The new tablet will not allow cancer cells to "treat ourselves"
Cancerous tumors are not in the least dangerous because they are very stable and have a high capacity for self-healing even after very severe injuries. But what if you deprive the cancer of this "bonus" cells? Such an approach could make them less resistant to treatments. And just such a method has been developed by researchers from the UK, creating new drug in tablet form.
A new drug developed jointly by researchers from the Institute of Francis Crick and Oxford University, is aimed at the tumor cells found in vulnerability. The fact that some types of cancer (in particular, the majority of cancer intestine) developed due to the lack of a particular protein AhR - Aryl hydrocarbon Receptor (aryl hydrocarbon receptor). And to replace it quite suitable I3C substance - Indole-3-Carbinol (indole-3-carbinol). According to one of the authors, Dr. Amina Metidzhi,
"We studied mice that can not produce or activate AhR in the intestine, and found that they easily develop inflammatory bowel disease, which progresses to cancer. But if in their diet to add I3C, inflammation and cancer does not develop. Moreover, even cancer patients already transfer to food of mice with I3C causes a decrease in malignancy, and reducing the size of the tumors themselves, making them less resistant to conventional therapies. '
When "substitution" of one another protein reduces the ability of tumor cells to self-regeneration and increased vulnerability and the permeability of cell membranes. Thus, tumors are more vulnerable to radiotherapy and chemotherapy, which leads to the fact that it is possible to dispense either lower doses, resulting in less damage to healthy tissues, or to ensure that the same dose treatment will operate more efficiently.